Expert Interview
Exploring Keryx’s Auryxia in treating CKD anemia after Nov 6th PDUFA
Ticker(s): KERXA nephrologist with experience in treating iron deficiency anemia in non-dialysis dependent CKD patients.
Please describe your clinical practice, in particular treating CKD patients and dealing with low hemoglobin levels in these patients.
Added By: c_adminHow many patients with CKD anemia develop an intolerance to oral iron supplements, or are non-responsive based on your experience?
Added By: c_adminHow likely would you be quick to prescribe Aurexia to your patients. Which patients do you see as ideal candidates for this drug?
Added By: c_adminDiarrhea is cited as the most common adverse effect of oral iron supplements; how big of an issue is it to patients?
Added By: c_adminIn the Phase 3 trial, ferric citrate raised hemoglobin levels by >1 g/dL for 52% of the patients after 16 weeks. Is this a satisfying result, considering patients started at hemoglobin levels between 9.0 g/dL and 11.5 g/dL?
Added By: c_adminWhat is the underlying mechanism of action of ferric citrate? Does it improve the natural absorption rate of iron from diet?
Added By: c_adminOn a scale of 1-10, 10 being extremely excited, how would you rate your level of excitement for Aurexia in treating CKD anemia?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
